CD19/CD20/CARVAC-targeted Chimeric antigen receptor gene-modified T cells therapy in Patients with relapsed/refractory B cell malignancies: An open-labled, single-center clinical study of the efficacy and safety
Latest Information Update: 05 Feb 2020
At a glance
- Drugs Anti-CD19/CD20 chimeric antigen receptor T cell therapy-Guiguidan Biomedicine (Primary)
- Indications B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms SuperCARTRRB1.0
Most Recent Events
- 05 Feb 2020 New trial record